Aro Biotherapeutics raises $24M of $100M target to advance Pompe disease therapy


The company expects to begin human clinical testing of its lead drug candidate later this year.

Previous Utility service provider DirectAir signs new lease in West Chester Township
Next University of Kansas Health System finalizes combination with Olathe Health